OBJECTIVE: This study aims to assess the use of Semmes-Weinstein monofilaments (SWMs) and of the Chemotherapy-Induced Neurotoxicity Questionnaire (CINQ) in the detection of chemotherapy-induced peripheral neuropathy (CIPN). METHOD: It is a comparative and cross-sectional study performed in a philanthropic general hospital, located in the state of Minas Gerais, Brazil. One hundred seventeen individuals have participated in this study; they were divided into two groups: patients (n = 87) treated with oxaliplatin, paclitaxel, or docetaxel and controls (n = 30) without malignant disease. RESULTS: There were statistically significant differences between groups for all symptoms assessed by means of the CINQ. Lower limbs were more severely affected. Patients had increased frequency and severity of changes in all points assessed with SWM compared with controls. In the analyses of concordance between CINQ and SWM, kappa = 0.320 (p < 0.001) was obtained, and there was a moderate and positive correlation (ρ = 0.357; p < 0.001). CONCLUSION: CINQ and SWM may be valid tools for diagnosing CIPN in oncology practice. SWM may identify subclinical CIPN.
OBJECTIVE: This study aims to assess the use of Semmes-Weinstein monofilaments (SWMs) and of the Chemotherapy-Induced Neurotoxicity Questionnaire (CINQ) in the detection of chemotherapy-induced peripheral neuropathy (CIPN). METHOD: It is a comparative and cross-sectional study performed in a philanthropic general hospital, located in the state of Minas Gerais, Brazil. One hundred seventeen individuals have participated in this study; they were divided into two groups: patients (n = 87) treated with oxaliplatin, paclitaxel, or docetaxel and controls (n = 30) without malignant disease. RESULTS: There were statistically significant differences between groups for all symptoms assessed by means of the CINQ. Lower limbs were more severely affected. Patients had increased frequency and severity of changes in all points assessed with SWM compared with controls. In the analyses of concordance between CINQ and SWM, kappa = 0.320 (p < 0.001) was obtained, and there was a moderate and positive correlation (ρ = 0.357; p < 0.001). CONCLUSION:CINQ and SWM may be valid tools for diagnosing CIPN in oncology practice. SWM may identify subclinical CIPN.
Authors: Anna-Liisa Kautio; Maija Haanpää; Hannu Kautiainen; Arto Leminen; Eija Kalso; Tiina Saarto Journal: Anticancer Res Date: 2011-10 Impact factor: 2.480
Authors: Eric P Winer; Donald A Berry; Susan Woolf; David Duggan; Alice Kornblith; Lyndsay N Harris; Richard A Michaelson; Jeffrey A Kirshner; Gini F Fleming; Michael C Perry; Mark L Graham; Stewart A Sharp; Roger Keresztes; I Craig Henderson; Clifford Hudis; Hyman Muss; Larry Norton Journal: J Clin Oncol Date: 2004-06-01 Impact factor: 44.544
Authors: C M L Driessen; K M E de Kleine-Bolt; A J J M Vingerhoets; F Mols; G Vreugdenhil Journal: Support Care Cancer Date: 2011-12-09 Impact factor: 3.603
Authors: Melisa L Wong; Bruce A Cooper; Steven M Paul; Gary Abrams; Kimberly Topp; Kord M Kober; Margaret A Chesney; Melissa Mazor; Mark A Schumacher; Yvette P Conley; Jon D Levine; Christine Miaskowski Journal: Support Care Cancer Date: 2019-02-15 Impact factor: 3.603
Authors: Dong-Woo Kang; Rebekah L Wilson; Paola Gonzalo-Encabo; Mary K Norris; Marybeth Hans; Meghan Tahbaz; Jackie Dawson; Danny Nguyen; Amber J Normann; Alexandra G Yunker; Nathalie Sami; Hajime Uno; Jennifer A Ligibel; Steven D Mittelman; Christina M Dieli-Conwright Journal: Front Oncol Date: 2022-06-20 Impact factor: 5.738
Authors: Paola Gonzalo-Encabo; Rebekah L Wilson; Dong-Woo Kang; Mary K Norris; Hajime Uno; Cami N Christopher; Christina Chow; Nathalie Sami; Frank S Fox; Jennifer A Ligibel; Christina M Dieli-Conwright Journal: Front Oncol Date: 2022-05-10 Impact factor: 5.738